HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer Middle East and Africa Asia Pacific

Industry Roundup

This article was originally published in The Tan Sheet

  • News

Executive Summary

PowerBar plant closing; Medifast, investor agree on board changes; BioPharmX announces IPO; Mérieux expands southeast U.S. testing; more news in brief.

You may also be interested in...



Omega-3 Petition Seeks Unqualified Blood Pressure, CHD Claims

The trade group Global Organization for EPA and DHA Omega-3 petitions FDA for an unqualified health claim related to reduced blood pressure as a surrogate marker for coronary heart disease risk.

In Brief

FDA finalizes OTC dosing guidance

European Commission Reshuffle Sees New Innovation Focus For Devices

Changes have occurred in the management focus within the European Commission’s directorate responsible for medtech but not within the devices leadership; familiar faces remain.

Table

View full table

Topics

Tags:
Consumer Middle East and Africa Asia Pacific
Latest News

Eager But Wary: Industry Seeks More Useful, More Detailed Remote Regulatory Assessment Processes

US FDA Touts Benefits From Remote Assessments, Manufacturers Feel Burden – Trade Groups

PCPC Working To Ensure State EPR Programs Are ‘Least Onerous As Possible’

New UK Health Secretary Wants More OTCs Available And Greater Role For Pharmacists

See All
UsernamePublicRestriction

Register

RS123676

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By